HIV Excision Utilizing CRISPR/Cas9 Technology: Attacking the Proviral Quasispecies in Reservoirs to Achieve a Cure
- PMID: 25893217
- PMCID: PMC4399856
- DOI: 10.15406/moji.2014.01.00022
HIV Excision Utilizing CRISPR/Cas9 Technology: Attacking the Proviral Quasispecies in Reservoirs to Achieve a Cure
Abstract
Recently several gene-editing technologies developed are being explored for their potential utility in providing new and unique treatments for HIV. One of these technologies is the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas)9 system. This system is being explored for its utility against host genes important to HIV infection, namely the HIV coreceptor CCR5, and for excision of the integrated genome from infected cells by targeting selected genes or genomic regions, especially the HIV-1 promoter or long terminal repeat (LTR). One of the major hurdles with the development of this technology for use in patients is defining the LTR sequence spectrum within the viral quasispecies present in the integrated virus and how that effects the number of guide RNAs (gRNAs) required to completely excise all proviral genomes. In this study, the Drexel Medicine CNS AIDS Research and Eradication Study (CARES) Cohort was utilized to demonstrate that [1] the predominant sequence of the integrated proviral LTR within the PBMC compartment shows a decrease in the amount of variation per year regardless of the type of therapy; [2] predominant HIV-1 LTR sequence undergoes continued genetic change with respect to the predominant genotype in these cells for at least 6 years while on effective suppressive ART; [3] using next generation sequencing (NGS), to demonstrate that 4 of the 8 patient samples examined could have a complete gRNA regimen designed to target all known quasispecies; and [4] length of HAART therapy may reduce the number of gRNA required to eradicate provirus as shown by NGS and gRNA design for longitudinal samples of patient A0017 in the CARES cohort. Overall, these studies demonstrate the feasibility of addressing at least one of the major technological challenges of CRISPR/Cas9-mediated HIV-1 proviral genome eradication involving the effective targeting of all viral quasispecies in a given patient sample.
Keywords: CRISPR/cas9; HIV; excision; guide RNA; memory T cells.
Figures

Similar articles
-
Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.AIDS Rev. 2017 Oct-Dec;19(3):167-172. AIDS Rev. 2017. PMID: 29019352
-
Broad-Spectrum and Personalized Guide RNAs for CRISPR/Cas9 HIV-1 Therapeutics.AIDS Res Hum Retroviruses. 2018 Nov;34(11):950-960. doi: 10.1089/AID.2017.0274. Epub 2018 Aug 27. AIDS Res Hum Retroviruses. 2018. PMID: 29968495 Free PMC article.
-
Novel gRNA design pipeline to develop broad-spectrum CRISPR/Cas9 gRNAs for safe targeting of the HIV-1 quasispecies in patients.Sci Rep. 2019 Nov 19;9(1):17088. doi: 10.1038/s41598-019-52353-9. Sci Rep. 2019. PMID: 31745112 Free PMC article.
-
CRISPR/Cas9: a tool to eradicate HIV-1.AIDS Res Ther. 2022 Dec 1;19(1):58. doi: 10.1186/s12981-022-00483-y. AIDS Res Ther. 2022. PMID: 36457057 Free PMC article. Review.
-
The therapeutic application of CRISPR/Cas9 technologies for HIV.Expert Opin Biol Ther. 2015 Jun;15(6):819-30. doi: 10.1517/14712598.2015.1036736. Epub 2015 Apr 12. Expert Opin Biol Ther. 2015. PMID: 25865334 Free PMC article. Review.
Cited by
-
Computational Analysis Concerning the Impact of DNA Accessibility on CRISPR-Cas9 Cleavage Efficiency.Mol Ther. 2020 Jan 8;28(1):19-28. doi: 10.1016/j.ymthe.2019.10.008. Epub 2019 Oct 15. Mol Ther. 2020. PMID: 31672284 Free PMC article.
-
Application of CRISPR-Cas9 Gene Editing for HIV Host Factor Discovery and Validation.Pathogens. 2022 Aug 9;11(8):891. doi: 10.3390/pathogens11080891. Pathogens. 2022. PMID: 36015010 Free PMC article. Review.
-
Multiplexed tat-Targeting CRISPR-Cas9 Protects T Cells from Acute HIV-1 Infection with Inhibition of Viral Escape.Viruses. 2020 Oct 28;12(11):1223. doi: 10.3390/v12111223. Viruses. 2020. PMID: 33126728 Free PMC article.
-
Chemokine receptor type-5: a key regulator of immunity, disease pathogenesis, and emerging therapeutic target.Inflammopharmacology. 2025 Aug 8. doi: 10.1007/s10787-025-01871-2. Online ahead of print. Inflammopharmacology. 2025. PMID: 40779011 Review.
-
Multiplexed Simian Immunodeficiency Virus-Specific Paired RNA-Guided Cas9 Nickases Inactivate Proviral DNA.J Virol. 2021 Nov 9;95(23):e0088221. doi: 10.1128/JVI.00882-21. Epub 2021 Sep 22. J Virol. 2021. PMID: 34549979 Free PMC article.
References
-
- (UNAIDS) JUNPoHA Global Report: UNAIDS report on the global AIDS epidemic. 2013
-
- Siliciano JD, Siliciano RF. Recent developments in the search for a cure for HIV-1 infection: Targeting the latent reservoir for HIV-1. J Allergy Clin Immunol. 2014;134(1):12–19. - PubMed
-
- Kramer-Hammerle S, Rothenaigner I, Wolff H, Bell JE, et al. Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res. 2005;111(2):194–213. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources